Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.K. (FTSE) Healthcare Sector Analysis

UpdatedJun 24, 2026
DataAggregated Company Financials
Companies85
  • 7D1.4%
  • 3M-4.1%
  • 1Y23.2%
  • YTD-0.3%

In the last week, Healthcare has been flat. As for the the longer term, the industry is up 21% over the past 12 months. Earnings are forecast to grow by 11% annually.

Sector Valuation and Performance

Has the U.K. Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 24 Jun 2026UK£346.1bUK£104.1bUK£16.3b26x21.3x3.3x
Fri, 22 May 2026UK£352.8bUK£103.0bUK£16.1b25.4x21.9x3.4x
Sun, 19 Apr 2026UK£382.5bUK£101.3bUK£16.0b23.4x23.9x3.8x
Tue, 17 Mar 2026UK£366.6bUK£102.4bUK£16.2b21.8x22.6x3.6x
Thu, 12 Feb 2026UK£383.0bUK£100.4bUK£15.7b26.5x24.4x3.8x
Sat, 10 Jan 2026UK£359.5bUK£100.3bUK£15.0b22.9x24x3.6x
Mon, 08 Dec 2025UK£345.3bUK£100.7bUK£15.0b22.7x23x3.4x
Wed, 05 Nov 2025UK£330.7bUK£100.6bUK£14.4b23.5x23x3.3x
Fri, 03 Oct 2025UK£321.4bUK£98.4bUK£12.1b28.3x26.7x3.3x
Sun, 31 Aug 2025UK£309.7bUK£100.7bUK£12.0b28.8x25.8x3.1x
Tue, 29 Jul 2025UK£291.3bUK£100.0bUK£11.0b31.3x26.6x2.9x
Thu, 26 Jun 2025UK£280.7bUK£96.4bUK£10.7b31.7x26.3x2.9x
Sat, 24 May 2025UK£286.9bUK£96.9bUK£10.7b29.9x26.7x3x
Mon, 21 Apr 2025UK£273.3bUK£97.1bUK£9.7b28.6x28.3x2.8x
Wed, 19 Mar 2025UK£312.1bUK£98.1bUK£9.6b27.2x32.7x3.2x
Fri, 14 Feb 2025UK£310.9bUK£99.9bUK£9.4b29.3x33.1x3.1x
Sun, 12 Jan 2025UK£254.9bUK£87.4bUK£7.8b31.3x32.7x2.9x
Tue, 10 Dec 2024UK£252.6bUK£85.1bUK£7.5b28.3x33.5x3x
Thu, 07 Nov 2024UK£238.7bUK£83.1bUK£7.5b26.8x32x2.9x
Sat, 05 Oct 2024UK£273.3bUK£82.4bUK£8.9b29x30.8x3.3x
Mon, 02 Sep 2024UK£305.5bUK£82.1bUK£8.8b34.6x34.5x3.7x
Wed, 31 Jul 2024UK£283.6bUK£82.5bUK£9.4b33.4x30.1x3.4x
Fri, 28 Jun 2024UK£282.9bUK£82.0bUK£9.4b30.2x30x3.4x
Sun, 26 May 2024UK£293.7bUK£81.6bUK£9.4b31.3x31.3x3.6x
Tue, 23 Apr 2024UK£266.9bUK£82.1bUK£9.7b29.2x27.5x3.3x
Thu, 21 Mar 2024UK£257.7bUK£80.4bUK£9.6b34x26.9x3.2x
Sat, 17 Feb 2024UK£256.3bUK£79.8bUK£9.4b35.2x27.1x3.2x
Mon, 15 Jan 2024UK£279.0bUK£83.9bUK£10.6b38.8x26.3x3.3x
Wed, 13 Dec 2023UK£262.3bUK£84.6bUK£10.7b39.4x24.5x3.1x
Fri, 10 Nov 2023UK£265.9bUK£86.0bUK£11.0b40.9x24.3x3.1x
Sun, 08 Oct 2023UK£277.9bUK£85.7bUK£10.3b41.5x26.9x3.2x
Tue, 05 Sep 2023UK£271.2bUK£84.3bUK£10.2b43.8x26.6x3.2x
Thu, 03 Aug 2023UK£277.5bUK£83.7bUK£10.2b41.5x27.2x3.3x
Sat, 01 Jul 2023UK£280.3bUK£82.7bUK£7.9b44.3x35.6x3.4x
Price to Earnings Ratio

35.6x


Total Market Cap: UK£280.3bTotal Earnings: UK£7.9bTotal Revenue: UK£82.7bTotal Market Cap vs Earnings and Revenue0%0%0%
U.K. Healthcare Sector Price to Earnings3Y Average 27.7x202420252026
Current Industry PE
  • Investors are pessimistic on the British Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 20.9x which is lower than its 3-year average PE of 27.7x.
  • The industry is trading close to its 3-year average PS ratio of 3.3x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 27% per year over the last three years.
  • Revenues for these companies have grown 7.8% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the U.K. Healthcare sector?

GB Market-1.14%
Healthcare1.43%
Pharma1.62%
Medical Equipment-0.50%
Biotech-1.97%
Healthcare Services-2.95%
Life Sciences-3.18%
Healthtech-6.87%
Industry PE
  • Investors are most optimistic about the Healthtech industry which is trading above its 3-year average PE ratio.
    • Analysts are expecting annual earnings growth of 17.3%, which is lower than the prior year's growth of 51.1% per year.
Forecasted Growth
  • Analysts are most optimistic on the Life Sciences industry, expecting annual earnings growth of 57% over the next 5 years.
  • In contrast, the Pharma industry is expected to see its earnings grow by 10% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
AZN AstraZenecaUK£135.902.3%
+UK£4.7b		31.5%PE26.8x
GSK GSKUK£19.580.4%
+UK£298.8m		38.8%PE13.4x
HIK Hikma PharmaceuticalsUK£15.153.3%
+UK£102.3m		-26.5%PE10.6x
AMS Advanced Medical Solutions GroupUK£2.4514.0%
+UK£64.9m		18.6%PE53.3x
HCM HUTCHMED (China)UK£1.581.3%
+UK£17.2m		-31.6%PE3.9x

Latest News

IDHC
US$0.50
Integrated Diagnostics Holdings
7D
-11.4%
1Y
40.1%
HIK
UK£15.15
Hikma Pharmaceuticals
7D
3.3%
1Y
-26.5%
GNS
UK£21.10
Genus
7D
-4.8%
1Y
7.9%
Narrative Update • Jun 22

GNS: Margin Discipline And New Bank Coverage Will Support Medium Term Upside

Analysts have maintained their fair value estimate for Genus at £37.00, with recent research indicating that this figure represents a balance between differing new views from JPMorgan and BNP Paribas on the stock's prospects. Analyst Commentary Recent coverage of Genus reflects a split in opinion, with some bullish analysts highlighting upside potential while others strike a more cautious, neutral tone.
CTEC
UK£2.07
Convatec Group
7D
-1.1%
1Y
-28.4%
Narrative Update • Jun 22

CTEC: Advanced Wound Care Pipeline Will Support Future Rerating Potential

Convatec Group's analyst price targets have been trimmed, with recent moves such as Citi cutting its view to £2.30 from £2.50 and JPMorgan to £2.94 from £3.07, highlighting a more cautious stance even as analysts point to steady assumptions on fair value, discount rate, revenue growth, profit margin and future P/E in their updated models. Analyst Commentary Recent research on Convatec Group points to a mixed but engaged view from the Street, with some analysts trimming price targets while others make supportive adjustments that reflect differing opinions on valuation, execution and growth potential.
PRTC
UK£1.32
PureTech Health
7D
1.9%
1Y
4.1%
New Narrative • Jun 22

Hub And Spoke Model Will Unlock Multiple Royalty Streams Over The Long Term

Catalysts About PureTech Health PureTech Health is a Boston based biotherapeutics company that creates and scales drug programs through a hub and spoke structure backed by external capital. What are the underlying business or industry changes driving this perspective?
SPEC
UK£0.97
INSPECS Group
7D
14.8%
1Y
98.0%
AZN
UK£135.90
AstraZeneca
7D
2.3%
1Y
31.5%
Analysis Article • Jun 19

AstraZeneca (LSE:AZN) Stock Could Be 20.2% Below Fair Value After Recent Pullback

AstraZeneca (LSE:AZN) is back in focus after recent share price pressure, with the stock down about 5% over the past month and past 3 months. This has prompted investors to reassess its long term profile. See our latest analysis for AstraZeneca. Despite the recent share price decline, with the stock down 5.3% on a 90 day share price return basis and currently trading at £131.54, AstraZeneca still shows a 73.7% total shareholder return over five years. This suggests long term holders have seen...
GSK
UK£19.58
GSK
7D
0.4%
1Y
38.8%
BVXP
UK£18.00
Bioventix
7D
5.9%
1Y
-32.1%
HCM
UK£1.58
HUTCHMED (China)
7D
1.3%
1Y
-31.6%
AGY
UK£0.07
Allergy Therapeutics
7D
-6.7%
1Y
0%
SN.
UK£11.18
Smith & Nephew
7D
-1.1%
1Y
2.3%
CVSG
UK£11.51
CVS Group
7D
-3.8%
1Y
-8.7%
Narrative Update • Jun 06

CVSG: Activist Buyback Push And Index Inclusion Will Support Future Upside

Analysts have kept their £16.40 fair value estimate for CVS Group broadly unchanged, with a slightly higher discount rate and modest tweaks to revenue growth, profit margin and future P/E assumptions helping to frame a neutral stance following recent Street research. What's in the News Converium Capital Inc.
ONT
UK£1.15
Oxford Nanopore Technologies
7D
-3.5%
1Y
-7.5%
AMS
UK£2.45
Advanced Medical Solutions Group
7D
14.0%
1Y
18.6%
CRW
UK£13.50
Craneware
7D
-7.0%
1Y
-37.5%